LMNA and osteoporosis: While zoledronate is an aminobisphosphonate agent known for its action against osteoporosis, and pravastatin belongs to the statins family known for their anticholesterol properties, the ZoPra treatment was shown to inhibit both farnesylation and geranylgeranylation of the progerin and prelamin A proteins, which permits higher permeabilization of the nuclear membranes to protein trafficking [48].